Yahoo
NasdaqGS - Nasdaq Real Time Price USD

Amphastar Pharmaceuticals, Inc. (AMPH)

26.85 +0.51 (+1.96%)
As of 2:32:03 PM EDT. Market Open.
Trade AMPH on Coinbase

Key Executives

Amounts are as of December 31, 2025 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
Name Title Pay Exercised Year Born
Dr. Ziping Luo Ph.D.
Chairman of the Board, Chief Scientist & COO 1.25M 2.53M 1950
Dr. Yongfeng Zhang Ph.D.
Co-Founder, President, CEO, Chief Scientific Officer & Director 1.71M 6.04M 1947
Mr. William J. Peters M.B.A.
CFO, Executive VP of Finance, Treasurer & Director 1.15M 106.88k 1968
Mr. Jacob Liawatidewi M.B.A.
Executive VP of Sales, Marketing & Corporate Administration Center, Corporate Secretary and Director 853.85k -- 1974
Mr. Rong Zhou M.S.
Senior EVP of Production & EVP of Scientific Affairs 1.14M 145.49k 1959
Mr. Dan Dischner M.B.A.
Senior Vice President of Human Resources & Corporate Communication -- -- --
Tony Marrs M.B.A., M.P.H., M.S.
Executive VP of Regulatory Affairs & Clinical Operations -- -- --

Amphastar Pharmaceuticals, Inc.

11570 6th Street
Rancho Cucamonga, CA 91730
United States
909 980 9484 https://www.amphastar.com
Sector: 
Healthcare
Full Time Employees: 
1,976

Description

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Glucagon for injection emergency kit; Enoxaparin, an injectable form of low molecular weight heparin for the prevention and treatment of deep vein thrombosis; and REXTOVY and Naloxone for opioid overdose. The company also provides Cortrosyn, a lyophilized power for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency; Amphadase, a bovine-sourced hyaluronidase injection; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; and emergency syringe products, including atropine, calcium chloride, dextrose, epinephrine, lidocaine, and sodium bicarbonate. In addition, it offers Albuterol sulfate inhalation aerosol for the treatment or prevention of bronchospasm; Iron sucrose injection, an iron replacement product for the treatment of iron deficiency anemia in patients with chronic kidney disease; Teriparatide injection for managing daily osteoporosis therapy; and Ipratropium Bromide HFA inhalation aerosol, an anticholinergic indicated for the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease. Further, the company provides active pharmaceutical ingredient (API) products, such as Recombinant Human Insulin and porcine insulin API. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

Corporate Governance

Amphastar Pharmaceuticals, Inc.’s ISS Governance QualityScore as of October 1, 2026 is 6. The pillar scores are Audit: 3; Board: 9; Shareholder Rights: 5; Compensation: 5.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

November 5, 2026 at 8:00 PM UTC

Amphastar Pharmaceuticals, Inc. Earnings Date

Recent Events

August 6, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

July 13, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

July 8, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

June 3, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

May 7, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

April 13, 2026 at 12:00 AM UTC

DEF 14A: Proxy Statements

March 16, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

March 6, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

February 26, 2026 at 12:00 AM UTC

10-K: Periodic Financial Reports

January 12, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

Related Tickers

Mobilize your Website
View Site in Mobile | Classic
Share by: